Abstract / Description of output
Drug-Induced Liver Injury (DILI) is a potentially fatal adverse event and a leading cause
for pre- and post-marketing drug withdrawal. Several multinational DILI initiatives have now rec-
ommended a panel of protein and microRNA (miRNA) biomarkers that can detect early liver injury
and inform about mechanistic basis. This manuscript describes the development of seqCOMBO, a
unique combo-multiplexed assay which combines the dynamic chemical labelling approach and an
antibody dependant method on Luminex MAGPIX system. SeqCOMBO enables a versatile multi-
plexing platform to perform qualitative and quantitative analysis of proteins and miRNAs in patient
serum samples simultaneously. To the best of our knowledge, this is the first method to profile
protein and miRNA biomarkers to diagnose DILI in a single step assay.
for pre- and post-marketing drug withdrawal. Several multinational DILI initiatives have now rec-
ommended a panel of protein and microRNA (miRNA) biomarkers that can detect early liver injury
and inform about mechanistic basis. This manuscript describes the development of seqCOMBO, a
unique combo-multiplexed assay which combines the dynamic chemical labelling approach and an
antibody dependant method on Luminex MAGPIX system. SeqCOMBO enables a versatile multi-
plexing platform to perform qualitative and quantitative analysis of proteins and miRNAs in patient
serum samples simultaneously. To the best of our knowledge, this is the first method to profile
protein and miRNA biomarkers to diagnose DILI in a single step assay.
Original language | English |
---|---|
Journal | Analytica |
DOIs | |
Publication status | Published - 3 Oct 2021 |
Keywords / Materials (for Non-textual outputs)
- dynamic chemical labelling (DCL)
- drug-induced liver injury (DILI)
- miRNA-122
- Luminex MAGPIX
- Liquid Biopsy
- antibody-dependant method